1Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in health volunteers[ J ]. Eur J Clin Pharmacol, 1999,55 : 199 - 203.
2Lindholm A, McEwen J, Riis AP. Improved postprandial glycaemic control with insulin aspart-randomized double-blind crossover trial in type 1 diabetes mellitus [ J ]. Diabetes Care,1999,22 : 801 - 805.
3Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients[ J ], Diabetes Care, 1998,21 : 1901 - 1909.
4Colagiuri S, Heller S, Vaaler B, et al. Insulin aspart reduces the frequency of nocturnal hypoglycaemia in patients with type 1 dianbetes[J]. Diabetologia ,2001,44(Suppl 1) :A210.
5Data from the UK Prospective Diabetes Study presented at 34th Annual Meeting,European Society for the study of Diabetes[ R].Barcelona, Spain, 1998.
6Ebeling P, Jansson P A, Smith U, et al. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin[J]. Diabetes Care, 1997,20 : 1287-1289.
7Rosskamp R H, Park G. Long-acting insulin analogs[J].Diabetes Care,1999, 22(Suppl 2) :B109-B113.
8Vajo Z, Fawcett J, Duckworth W C. Recombinant DNA technology in the treatment of diabetes [ J]. Endocr Rev, 2001,22:706-717.
9McKeage K, Goa K L. Insulin Glargine [ J ]. Drugs, 2001,61 :1599-1624.
10Heinemann L, Linkeschova R, Rave K. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo[J]. Diabetes Care, 2000,23 : 644-649.
